CA-EVIDATION
16.11.2023 15:01:58 CET | Business Wire | Press release
Evidation — the company creating new ways to measure and improve health in everyday life — today announced a landmark partnership with Our Future Health, a national health research initiative and collaboration between the UK’s National Health Service (NHS), public health agencies, non-profits, and leading life sciences companies. Our Future Health will deploy Evidation’s enterprise digital health engagement and measurement platform to conduct a multi-year, longitudinal research program for up to five million participants across the UK.
“Evidation and Our Future Health believe that deeply understanding individuals' everyday health experiences can accelerate discoveries that will transform health," said Christine Lemke, Co-founder and CEO of Evidation. "Together, with the participation of millions of volunteers across the UK, we will enable research that can advance more inclusive and effective ways to prevent, detect, and treat disease."
“Our Future Health aims to be a world-leading resource for health research,” said Dr Raghib Ali OBE, Chief Executive of Our Future Health. “Evidation has extensive expertise measuring and characterizing health in everyday life and engaging people at scale. This, combined with their experience in deploying large research and engagement programs and their shared commitment to the highest standards of data protection and user privacy, makes them the ideal partner for Our Future Health.”
Our Future Health is bringing together up to five million people to develop new ways to prevent, detect and treat diseases. To achieve this, Our Future Health will recruit a diverse and inclusive cohort of people across the UK who have consented to participate. The program population accounts for almost 10% of the UK’s adult population of over 53 million people. Evidation’s technology will power the digital experience, including a participant-facing app and technology infrastructure, that makes this massive research initiative possible. This new digital experience will be developed in the coming months.
Evidation’s platform is the technology layer that powers health research and engagement programs for some of the world’s leading healthcare organizations. Evidation makes it possible to harness real-world data — including wearables and survey data — to deeply understand health experiences rapidly and longitudinally, in large populations. Refined over a decade, Evidation’s measurement and engagement platform helps capture health data from outside the clinic and rewards participants for taking healthy actions.
About Evidation
Evidation creates new ways to measure and improve health in everyday life — making proactive, personalized, and truly human-centered healthcare possible. By connecting directly with millions of individuals, Evidation harnesses real-world data to deeply understand health experiences, rapidly and at scale. Evidation’s privacy-centric digital health measurement and engagement platform uses data science and machine learning to translate these everyday insights into high-impact health guidance, treatments, and tools. Founded in 2012, Evidation is headquartered in California with employees working around the globe. Learn more at www.evidation.com.
About Our Future Health
Our Future Health is a collaboration between the public, private and charity sectors. It aims to be the UK’s largest health research program, bringing people together to develop new ways to prevent, detect and treat disease.
Our Future Health is committed to the highest standards, policies and processes that protect participants’ confidentiality, whilst maximizing the opportunity to help researchers to tackle serious diseases. Participants’ data is de-identified and held securely in trusted research environments that meet strict security criteria. There is a robust and transparent access process to ensure appropriate research access to Our Future Health data and samples for registered researchers. All researchers are held to the same standards.
Our Future Health is a member of the UK Health Data Research Alliance, the independent alliance of leading healthcare and research organizations establishing best practice for the ethical use of UK health data for research at scale.
Our Future Health is a company limited by guarantee registered in England and Wales (number 12212468) and a charity registered with the Charity Commission for England and Wales (charity number 1189681) and OSCR, Scottish Charity Regulator (charity number SC050917).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116712663/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 16:04:00 CEST | Press release
At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta
Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 15:21:00 CEST | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
